StockNews.com cut shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a sell rating in a research note released on Thursday. Separately, Stifel Nicolaus upped their price objective on shares of Compugen from $3.00 to $4.00 and gave the company a buy rating in a report on Tuesday, December 19th. Two analysts […]
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year target […]
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has received an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price […]
Compugen (NASDAQ:CGEN – Get Free Report) had its target price raised by investment analysts at Stifel Nicolaus from $3.00 to $4.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target suggests a potential upside of […]
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has received an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among analysts […]